Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis ; volume:24 ; number:1 ; day:18 ; month:10 ; year:2024 ; pages:1-8 ; date:12.2024
BMC cancer ; 24, Heft 1 (18.10.2024), 1-8, 12.2024
- Urheber
-
Cui, Manlu
Fu, Juan
Li, Qiuyun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-13052-5
- URN
-
urn:nbn:de:101:1-2501072129253.673914204321
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cui, Manlu
- Fu, Juan
- Li, Qiuyun
- SpringerLink (Online service)
Ähnliche Objekte (12)
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy
Radiotherapy refusal in breast cancer with breast-conserving surgery
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy
Radiotherapy refusal in breast cancer with breast-conserving surgery
PYK2 promotes HER2-positive breast cancer invasion
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Breast diseases : breast-conserving therapy, non-invasive therapy, mastopathy